Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic
company, and Farmingdale State College today announced they are
partnering to provide molecular and antibody testing for COVID-19
to the campus community as the college reopens this summer and
begins classes in the fall.
“This program fits perfectly into this fall’s campus plans
designed by our COVID-19 Task Force, and testing our students with
no required financial outlay is important,” said Farmingdale State
College President John S. Nader. “Nothing is more critical than
ensuring the safety and welfare of our campus community.”
Testing by Enzo is a component of Farmingdale’s comprehensive
fall campus plan, which also includes mandatory face coverings,
social distancing, and delivery of classes through a combination of
face-to-face, remote learning, and online instruction. Executing
under Enzo’s School and Institution Testing (“SIT”) Program, the
collaboration will provide the necessary level of safety for
students, staff, and faculty at the college this fall.
FSC’s Health and Wellness Director Kevin Murphy said, “Students
and employees will be given a test prescription through the Health
and Wellness Center. There will be several pre-scheduled testing
clinics onsite each month at the College. Any campus member who
needs to be tested immediately will be prioritized at Enzo’s
clinical laboratory located near the campus in Farmingdale.”
Kara Cannon, Chief Commercial Officer of Enzo said, “Enzo is
launching its School and Institution Testing (“SIT”) Program to
ensure well-being, security, and compliance at educational and
religious institutions. Farmingdale State College is the first to
leverage Enzo’s expertise and enable this academic institution to
safely forge a course forward this summer into the fall.”
To deliver on the program objectives, Enzo is drawing on its
Long Island-based Center of Excellence to provide the high-level
products and services for which the company has become known. Enzo
tests are developed and manufactured at its Farmingdale GMP
facility relying on over 40 years of research and manufacturing
expertise.
Enzo’s Long Island-based operations, which include a clinical
diagnostic CLIA (high complexity) lab, enable COVID-19 molecular
testing regardless of a student’s insurance status. Testing will be
conducted both on campus as well as at Enzo’s facilities using its
highly sensitive molecular AMPIPROBE® SARS-CoV-2 swab test.
As staff return to campus in phases, Enzo will add serological
antibody blood testing (IgG) as well. Furthermore, Enzo will be
available to provide additional testing including expanded antibody
(IgM, IgA) testing.
To promote physical distancing, the College has converted
multiple areas for instructional use and built a schedule that
limits the number of students on campus at any given time. Only
one-third of residential rooms will be occupied in the fall and by
only one student. A residential hall has been reserved for students
who test positive for COVID-19 and require a 14-day quarantine.
Enzo President Barry Weiner commented: “It is my hope that
Farmingdale State College will serve as a model for other SUNYs and
higher education institutions seeking COVID-19 testing solutions
for their students, faculty, and administration. We believe that
large-scale testing may help curtail the spread of the disease. Our
SIT program has been launched to address concerns from many
constituents regarding the opening of schools and religious
institutions in the coming weeks and months.”
Leveraging decades of molecular and serological expertise, Enzo
has been at the forefront of COVID-19 testing since the pandemic
arrived in the United States. Experts agree that COVID-19 molecular
testing is the most effective way to contain the spread of the
virus. Enzo is unique in its full vertically integrated structure
with reagent manufacturing capabilities, proprietary diagnostic
instruments, and lab services. Enzo Clinical Labs is a New York
State Department of Health regulated full-service clinical
reference laboratory.
Enzo previously published a white paper detailing its
Comprehensive COVID-19 Program and recently published a more
specific white paper detailing its COVID-19 Antibody Screening
Program.
Both white papers are available on Enzo’s website at:
https://www.enzo.com/coronavirus.
About Enzo Biochem Enzo
Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
About Farmingdale State College
As the largest of SUNY’s colleges of technology (10,000
students), Farmingdale State College equips students with the
resources and knowledge sought by today’s emerging industries.
Offering both bachelor and associate degrees, FSC introduced its
first Master’s degree – Technology Management - in 2017. At
FSC, students learn in small, personalized classes and have
abundant opportunities for applied learning—internships, clinical
training, and guided research—that provide practical instruction
and personal growth. For more information, go to
Farmingdale.edu
Forward-Looking Statements
Except for historical information, the matters
discussed in this release may be considered "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its
management, including those related to cash flow, gross margins,
revenues, and expenses which are dependent on a number of factors
outside of the control of the Company including, inter alia, the
markets for the Company’s products and services, costs of goods and
services, other expenses, government regulations, litigation, and
general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2019. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The
Company disclaims any obligations to update any forward-looking
statement as a result of developments occurring after the date of
this release.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO 212-583-0100 dbench@enzo.com
For Farmingdale State College.
Kathryn Coley, Senior Director of Communications 516-650-4247
coleyks@farmingdale.edu
Investors/Media:
Melanie SolomonThe Blueshirt
Group415-217-4964melanie@blueshirtgroup.com
Steve AnrederAnreder &
Company212-532-3232Steven.anreder@anreder.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Sep 2023 to Sep 2024